deliv better-than-anticip result organ growth
posit top neg estim organ growth
world-wide hip knee implant market track littl wors
initi anticip approxim year-over-year versu
forecast zbh market share loss similar last quarter
roughli bp year-over-year much better bp year-over-year
declin model unlik last quarter zbh revenu
upsid also flow earn adjust ep
forecast consensu expect adjust
oper margin exceed forecast bp debt pay
higher anticip
follow better-than-expect maintain adjust
ep guidanc rang despit expect increment
headwind adjust ep chang foreign currenc exchang
rate offset currenc headwind includ favor organ
growth outlook versu
previous sever million reduct anticip net interest expens
debt pay activ expect compani adjust
tax rate toward low end prior guidanc
zbh commentari earn call rel posit
compani indic suppli product produc biomet warsaw indiana
manufactur facil fulli return normal level earli
compani previous expect appear
make progress delay remain product appear manag
addit product launch intend address gap zbh knee portfolio
remain track lastli anyth new report regard
fda complianc depart review april
biomet warsaw manufactur facil zbh subsequ respons
compani continu believ observ impact
total debt total asset
thought consensu expect look littl
conserv surpris compani reiter adjust
ep guidanc thought combin currenc headwind minor
addit suppli delay would lead reduc adjust ep guidanc
lower half prior rang howev given better perform rel
hip knee implant market well tax interest expens opportun
rais adjust ep forecast
respect rate remain neutral given
stock run-up friday linger uncertainti regard fda view
zbh remedi effort biomet warsaw manufactur facil
import pleas read disclosur disclaim page report
report adjust ep consensu expect higher
estim rel forecast better-than-anticip revenu account upsid versu
adjust ep forecast adjust oper margin interest expens also slightli better
zbh revenu increas year-over-year million consensu expect
million million estim quarter zbh organ growth posit
neg forecast believ upsid versu consensu even higher
half estim consensu appear updat currenc chang
notabl also includ extra sell day year-over-year like contribut roughli bp zbh
organ growth quarter
adjust incom statement analysisnorthcoast research million except percent per share sg interest expens interest expens incom incom incom margin com share compani report northcoast research estim factset
product categori standpoint better-than-anticip organ growth zbh hip knee spine
craniomaxillofaci cmf busi account upsid rel revenu outlook
organ growth world-wide hip knee implant market track littl wors
initi anticip approxim year-over-year versu forecast zbh market share loss
similar last quarter roughli bp year-over-year much better bp year-
over-year declin model compani spine cmf busi also benefit particularli
strong quarter cmf product compani expect repeat
knee post organ growth posit flat estim quarter knee
implant market growth bounc back weak first quarter zbh market share loss narrow
bp year-over-year versu closer bp year-over-year geograph standpoint zbh
asia pacif knee busi bounc back soft america knee segment return growth
inc organ growth analysi reflect pro forma result zimmer biomet compani report northcoast organ growth analysisnorthcoast currenc constant currenc acquisit divestitur organ hip knee spine cmf dental compani report northcoast research estim first time sinc compani knee price growth also improv modestli year-over-year
declin year-over-year reduct
continu believ product suppli product gap drive market share loss knee regard
product gap compani continu expect full launch persona trabecular metal cementless tibia
persona revis knee rosa total knee applic also slate limit launch
back half year full launch given time launch zbh knee implant
busi like continu grow market rate anoth five quarter even address suppli issu
complet product launch in-lin forecast
hip post posit organ growth well forecast similar
knee saw sequenti improv america hip organ growth posit year-over-year
posit year-over-year product suppli condit began improv segment
contrast compani hip implant sale emea region remain weak organ
neg comp compani hurt market pressur unit kingdom departur
presid emea busi inabl compet certain tender contract restor full
suppli hip segment unlik knee year-over-year price declin zbh hip busi larg stabl
quarter year-over-year versu year-over-year declin steeper fall
time frame year-over-year
inc knee organ growth analysi reflect pro forma result zimmer biometsourc compani report northcoast
zbh adjust oper margin declin bp year-over-year slightli
forecast quarter adjust gross margin fell bp reflect continu price pressur
year-over-year increment manufactur expens work address qualiti issu
biomet warsaw product facil addit compani adjust sg expens increas bp year-
over-year sale made increment invest area includ sale forc effort turn
around organ growth perform
follow better-than-expect maintain adjust ep guidanc rang
despit expect increment headwind adjust ep chang foreign currenc exchang
rate offset currenc headwind includ favor organ growth outlook
versu previous sever million reduct anticip net interest expens
debt pay activ expect compani adjust tax rate toward low end
prior guidanc notabl also rais free cash flow guidanc
million million
inc hip organ growth analysi reflect pro forma result zimmer biomet compani report northcoast inc quarterli total compani price growth year-over-year compani
zbh commentari earn call rel posit compani indic suppli
product produc biomet warsaw indiana manufactur facil fulli return normal
level earli compani previous expect appear make progress delay
remain product appear manag given compani decis rais lower end organ
growth guidanc addit product launch intend address gap zbh knee portfolio remain track
lastli anyth new report regard fda complianc depart review
april biomet warsaw manufactur facil zbh subsequ respons compani
continu believ observ impact product suppli
summari thought consensu expect look littl conserv
surpris compani reiter adjust ep guidanc thought combin currenc
headwind minor addit suppli delay would lead reduc adjust ep guidanc lower
half prior rang howev given better perform rel hip knee implant market well
tax interest expens opportun rais adjust ep forecast
respect rate remain neutral given stock run-up friday
linger uncertainti regard fda view zbh remedi effort biomet warsaw
guidanc earn earn callrevenu growth currenc growth constant currenc growth yr/yr organ growth yr/yr acquisit growth ep growth yr/yr neg compani report northcoast research estim
inc annual incom statement analysi adjust northcoast research million except percentag per share gross gross sg sg oper oper net interest incom net interest incom incom incom incom tax minor incom extra incom extra extra net net wghd com share ep ep growth ep growth exclud amort intang asset adjust ep start compani report northcoast research estim disclosur
